ICCC

ImmuCell Corporation

ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

ImmuCell Corporation (ICCC) is scored daily on Deltasharpe Prism against Healthcare sector peers across five pillars: Value, Growth, Profitability, Momentum and Revisions.

Quantitative Factor Evaluation • Updated

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-12 C- (2.0) B+ (3.7) B (3.3) B (3.5) C+ (2.6) B- (3.0)
2026-11-05 C- (2.0) B+ (3.7) B (3.3) B (3.2) C+ (2.7) B- (3.0)
2026-10-29 C- (2.0) B+ (3.6) B (3.3) B- (3.1) C+ (2.7) B- (2.9)
2026-10-22 C- (2.0) B+ (3.6) B (3.3) B- (3.1) C+ (2.6) B- (2.9)

Showing the last month only. Subscribe for the full factor score history.

For more — Subscribe